Innovating Antibodies, Improving Lives

Investor Presentation
November 2020

Genmab

Forward Looking Statement

This presentation contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding our present and future business strategies and the environment in which we will operate in the future. The important factors that could cause our actual results, performance or achievements to differ materially from those in the forward looking statements include, among others, risks associated with product discovery and development, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of our products in patients, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Further, certain forward looking statements are based upon assumptions of future events which may not prove to be accurate. The forward looking statements in this document speak only as at the date of this presentation. Genmab does not undertake any obligation to update or revise forward looking statements in this presentation nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Our Core Purpose, Strategy & Vision Guide Our Work



Core Purpose

To improve the lives of patients by creating & developing innovative antibody products

Our Strategy

Turn science into medicine

Build a profitable & successful biotech

Focus on Core Competence

Vision

By 2025, our own product has transformed cancer treatment and we have a pipeline of knock-your-socks off antibodies

The Genmab Difference

Innovation Powerhouse Transforming Cancer Treatment & Creating Value

Track Record & Growth



Solid Foundation Built on a Differentiated Pipeline

Solid Financial Base

Approved Partnered Products

- DARZALEX® (daratumumab) / DARZALEX *FASPRO*™ (daratumumab and hyaluronidase-fihj)[1]
- Kesimpta® (ofatumumab)[2]
- TEPEZZA® (teprotumumab)[3]
- Arzerra® (ofatumumab)[4]

Potential 1st-in-Class/Best-in-Class

Our Own Clinical Pipeline

- Tisotumab Vedotin[5]
- Enapotamab Vedotin
- HexaBody®-DR5/DR5
- Epcoritamab (DuoBody®-CD3xCD20)[6]
- DuoBody-CD40x4-1BB[7]
- DuoBody-PD-L1x4-1BB[7]
- DuoHexaBody®-CD37[6]
- DuoBody-CD3x5T4[6]

Programs Built on Genmab's Innovation

Partner-owned Programs in the Clinic

- 15 product candidates in clinical development w/ partners
- Incl. 7 DuoBody products with Janssen, 1 with Novo Nordisk

R&D Engine

Technologies & Pre-Clinical

- DuoBody technology
- HexaBody technology
- HexElect® technology
- DuoHexaBody® technology
- Rich Pre-Clinical Pipeline incl. HexaBody-CD38[8]

[1]In dev. by Janssen; [2] in dev. by Novartis; [3]In dev. by Horizon; [4]Commercialized by Novartis, no longer in active development. [5]50:50 w/ Seattle Genetics; [6]50:50 w/ AbbVie; [7]50:50 w/ BioNTech, GEN1046 & GEN1042 respectively; [8]Genmab is developing HexaBody-CD38 in an exclusive worldwide license and option agreement with Janssen Biotech, Inc

DARZALEX® (daratumumab) & DARZALEX *FASPRO*™ (daratumumab and hyaluronidase-fihj): Redefining Treatment of Multiple Myeloma

First-in-class CD38 antibody in development to treat cancer

Collaboration with Janssen: Genmab entitled to tiered royalty of 12-20% of net sales

Approved in certain territories for various multiple myeloma (MM) indications[1]

DARZALEX *FASPRO* first and only SubQ CD38 mAb approved in U.S. for treatment of MM

2019 WW net sales by J&J: $2,998M



See local country prescribing information for approved indications

DARZALEX Approvals: US and EU

On Track for Approval Across All Lines of MM Treatment

US Approvals



EU Approvals



Daratumumab

Proving to be the Critical Driver Across Different Combinations & Treatment Lines

	Frontline				Relapsed/Refractory		
	Transplant Eligible		Transplant Ineligible				
	Ph 3 CASSIOPEIA[1,3] (D-VTd vs. VTd)	Ph 2 GRIFFIN[1,4] (D-VRd vs VRd)	Ph 3 ALCYONE[2,4] (D-VMP vs. VMP)	Ph 3 MAIA[2,4] (D-Rd vs. Rd)	Ph 3 POLLUX[2,4] (D-Rd vs. Rd)	Ph 3 CASTOR[2,4] (D-Vd vs Vd)	Ph 3 CANDOR[2,4] (D-Kd vs Kd)
sCR Odds Ratio[1] or CR+[2]	1.60	1.57	~2x	~2x	>2x	3x	~3x
MRD-neg rate	1.5x	2.5x	4x	>3x	~5x	>7x	~10x
PFS risk reduction	53%	NA	58%	44%	56%	69%	37%
	(HR, 0.47)		(HR, 0.42)	(HR, 0.56)	(HR, 0.44)	(HR, 0.31)	(HR, 0.63)

Ongoing Phase 3: CEPHEUS (D-VRd, NDMM NTE), PERSEUS (D-VRd, NDMM TE)

[3]Data as per ASCO 2019; [4]Data as per ASH 2019

Improved Survival for Patients with Multiple Myeloma

Overall Survival Analysis from ALCYONE Trial



Kaplan-Meier estimates of overall survival in intention-to-treat population. Mateos, MV et al, 'Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomized, open-label, phase 3 trial,' *The Lancet*, published online December 9, 2019

Kesimpta® (ofatumumab)

Approved in Relapsing Multiple Sclerosis

- Human CD20 Antibody – well validated target
- Injection for SubQ use approved for RMS in the US
- First B-cell therapy that can be self-administered by patients at home using Sensoready® autoinjector pen
- Developed by Novartis: Regulatory submission also made in EU
- Genmab 10% royalty payment of net sales
- Second Genmab-created product with blockbuster potential

Tisotumab Vedotin

Genmab's Most Advanced Asset with Potential in Solid Tumors

- Fully human antibody-drug conjugate (ADC) targeting Tissue Factor (TF) in development to treat solid tumors
- License and collaboration agreement with Seattle Genetics 50:50
- Very favorable topline results, Phase 2 recurrent or metastatic cervical cancer
- Ongoing trials in cervical, ovarian cancer, other solid tumors
- Expanding development, additional studies planned

Tisotumab Vedotin in Cervical Cancer

Designed to Address a High Unmet Medical Need

Recurrent or metastatic cervical cancer

- Poor prognosis advanced / recurrent cervical cancer
  - RR standard therapies generally <15%
  - Median OS 6-8 months
- Data ORR & survival after progression on 1L bevacizumab + doublet chemotherapy are limited

Conclusions*

(previously treated recurrent or metastatic cervical cancer)

- Compelling and durable antitumor activity with manageable and tolerable safety profile
- ORR 24%; CR: 7%
- Median DOR 8.3 mo
- Median PFS (4.2 mo) and OS (12.1 mo) encouraging

Clinically meaningful and durable responses observed*

	N=101
Confirmed ORR (95% CI),[a] %	**24 (15.9–33.3)**
CR, n (%)	7 (7)
PR, n (%)	17 (17)
SD, n (%)	49 (49)
PD, n (%)	24 (24)
Not evaluable, n (%)	4 (4)



*Data from innovaTV 204 study, Coleman R, et al. Tisotumab Vedotin in Cpreviously Treated Recurrent or Metastatic Cervical Cancer: Results from the Phase 2 innovaTV 204 / GOG-3023/ ENGOT-cx6 Study, ESMO September 21, 2020. Data cutoff: February 06, 2020. Median duration of follow-up: 10.0 months. CI, confidence interval; CR, complete response; DOR, duration of response; IRC, independent review committee; NR, not reached; ORR, objective response rate; PD, disease progression; PR, partial response; SD, stable disease.

Enapotamab Vedotin

Potential in Solid Tumors



- Fully human ADC, targets tumor-associated AXL
- AXL over-expressed on many resistant tumors
- Ph 1/2 study ongoing solid tumors
  Expansion cohorts recruiting
- ADC technology license from Seattle Genetics
- Fully owned by Genmab

Epcoritamab (DuoBody-CD3xCD20)

Potential for Improved Efficacy & Safety in B Cell Malignancies



- Potential best-in-class therapeutic
- T cell-mediated killing of CD20-expressing cells
- SubQ Ph 1/2 trials in B cell malignancies ongoing
- 50:50 co-development Genmab and AbbVie

Epcoritamab: Dose Escalation Data Presented at EHA25 Virtual Congress 2020*

Anti-tumor activity

- 86% ORR in FL ≥ 0.76mg
- 60% ORR, incl. 3 pts who failed prior CAR-T treatment, in DLBCL/HGBCL ≥12 mg
- Emerging prelim. data highly encouraging with substantial single-agent efficacy
- Induces rapid and deep responses in heavily pretreated pts with B-NHL across different subtypes

Safety

- No DLTs observed; MTD has not been reached
- No treatment-related deaths
- No discontinuation due to AEs unrelated to disease progression
- No Grade ≥ 3 CRS events observed



Dose-escalation data with subcutaneous epcoritamab indicate potential for best-in-class therapy

*Dose escaltion data presented on EHA25 Virtual Congress 2020 poster, Data cut-off dates: safety, April 24 2020; efficacy, May 14 2020

DuoHexaBody-CD37 (GEN3009)

Building Our Pipeline: First DuoHexaBody in the Clinic

- Combination of DuoBody & HexaBody platforms
- Novel target for hematologic malignancies
- Unique mechanism-of-action
- Dose escalation ongoing
- 50:50 co-development Genmab and AbbVie

DuoBody-CD3x5T4 (GEN1044)

Latest in the Clinic

- Based on proprietary DuoBody technology
- CD3 bispecific, T cell mediated cytotoxicity of 5T4+ tumor cells
- 5T4 expressed on multiple solid tumors limited expression in healthy tissue
- Dose-escalation ongoing
- 50:50 co-development Genmab and AbbVie

DuoBody-PD-L1x4-1BB (GEN1046)

Bispecific Next Generation Checkpoint Immunotherapy



- First-in-Class Bispecific antibody targeting PD-L1 & 4-1BB (CD137)
- Designed to activate T cells through conditional 4-1BB co-stimulation, while simultaneously blocking the PD1/PD-L1 axis
- Combining T cell stimulation with checkpoint blockade
- Ph 1/2 study ongoing in solid tumors
- 50:50 co-development Genmab and BioNTech

DuoBody-CD40x4-1BB (GEN1042)

Bispecific Agonistic Antibody

- Bispecific antibody targeting CD40 & 4-1BB (CD137)
- Conditionally activates T cells and APC in presence of CD40-expressing cells
- Phase 1/2 study ongoing in solid tumors
- 50:50 co-development Genmab and BioNTech

See local country prescribing information for approved indications

HexaBody-DR5/DR5 (GEN1029)

First HexaBody in Clinical Development



- Targets 2 distinct DR5 epitopes
- HexaBody platform - DR5 clustering & DR5 agonist activity
- First 100% Genmab-owned HexaBody product in clinic
- Phase 1/2 study ongoing in multiple solid tumors

2020 Guidance: Recurring Revenue Growth and Focused Investments

Income Statement	DKKM	~USDM*
Revenue	9,250 – 9,850	1,423 – 1,515
Operating Expenses	(3,850) – (3,950)	(592) – (608)
Operating Income	5,350 – 5,950	823 - 915

Key Observations

Summary P&L

- DARZALEX royalties of ~DKK 4.1bn to ~DKK 4.5bn to drive recurring revenue growth
- Nearly 90% of USD 750M upfront from AbbVie collab. recognized immediately
- Growth in operating expenses driven by expanding and accelerating our clinical pipeline

DARZALEX Sales of USD 3.9bn – USD 4.2bn

- Significant opportunity for growth in 1L MM market
- SubQ DARZALEX approvals in H1 in U.S. & EU
- Market share gain in the U.S. and RoW driven by uptake in all lines of treatment
- 8 approved indications in U.S., late stage to 1L MM

*2020 Guidance – November 4, 2020 / USD 1.00 = DKK 6.50.

Key 2020 Priorities

Building a Strong Differentiated Product Pipeline

Priority	✓	Targeted Milestones
Genmab proprietary* products	✓	» Tisotumab vedotin[1] - Phase 2 innovaTV 204 safety & efficacy analysis in recurrent/metastatic cervical cancer and engage U.S. FDA for BLA submission subject to trial results
	**	» Tisotumab vedotin - data on other solid tumor types
		» Enapotamab vedotin – data to support late stage development
	✓	» Epcoritamab (DuoBody-CD3xCD20)[2] Phase 1/2 – decision on recommended Phase 2 dose & initiate expansion cohorts
		» HexaBody-DR5/DR5 Phase 1/2 - advance dose escalation
	✓	» DuoBody-PD-L1x4-1BB[3] Phase 1/2 – initiate expansion cohorts
		» DuoBody-PD-L1x4-1BB initial data in H2 2020
	✓	» File INDs and/or CTAs for 2 new products
Daratumumab[4]	✓	» U.S. FDA and EMA decision on Phase 3 COLUMBA multiple myeloma SubQ submission
	✓	» sBLA and MAA Submission Phase 3 ANDROMEDA amyloidosis
		» sBLA and MAA submission Phase 3 APOLLO multiple myeloma
Ofatumumab[5]	✓	» U.S. FDA decision on regulatory dossier submission in multiple sclerosis
Teprotumumab[6]	✓	» U.S. FDA decision on Phase 3 OPTIC active thyroid eye disease submission

*Certain product candidates in development with partners, as noted.
**Data anticipated in 2021
1. 50:50 dev. w/ Seattle Genetics; 2. 50:50 dev w/ AbbVie; 3. 50:50 dev. w/ BioNTech; 4. In dev. by Janssen; 5. In dev. by Novartis; 6. In dev. by Horizon Therapeutics

Delivering on Genmab's Promise:

Innovating Antibodies, Improving Lives

Developing new capabilities to bring own product to market

World-class team with track record of success

Significant earnings potential from marketed products

Unique R&D engine & strategic alliances

Pipeline of 1st-in-class / best-in-class therapies advancing through clinic

Innovating Antibodies, Improving Lives

Appendix

Genmab

A Leading International Biotech With Large Free Float



As of September 30, 2020

Genmab & AbbVie: Collaboration Overview

A broad, long-term oncology collaboration with Genmab and AbbVie working together to jointly make all strategy, clinical development and commercialization decisions

50/50 partnership across three clinical next-generation bispecific antibody product candidates (epcoritamab, DuoHexaBody-CD37, DuoBody-CD3x5T4)

Genmab to book epcoritamab sales in the U.S. and Japan; AbbVie to commercialize epcoritamab RoW - Genmab to receive tiered royalties on RoW net sales

Worldwide co-commercialization and profit split of all other programs

Discovery Research Collaboration

Fourth* largest oncology partnership with total potential value ~USD 3.9bn (up-front cash + milestone payments) to Genmab

*Source: Company information and filings.

Advancing Pipeline: Delivering on Our Promise & Creating Value

Accelerating Development of Potential “Next Winners”

DuoBody-CD3xCD20 (epcoritamab)

- **Potential best-in-class:** SubQ administration
- Pre-clinical / preliminary clinical data shows encouraging safety & efficacy
- Expeditious and comprehensive clinical development plan
- RP2D decision & expansion cohorts initiation
- 50:50 AbbVie

DuoBody-PD-L1x4-1BB (GEN1046)

- **Potential first-in-class:** Next generation IO
- Unmet medical need
- FiH clinical study: escalation phase is ongoing
- 50:50 BioNTech

Track Record of Success

Advancing Pipeline: Delivering on Our Promise & Creating Value

Bolstering early stage portfolio

- DuoBody-CD40x4-1BB[1]; DuoHexaBody-CD37[2]; DuoBody-CD3x5T4[2]; HexaBody-CD38[3]

Adding new technologies

Data sciences

Expanding early stage discovery programs

Enhancing clinical development capabilities

Track Record of Success

[1]GEN1042, 50:50 w/ BioNTech; [2]50:50 w/ AbbVie; [3]Genmab is developing HexaBody-CD38 in an exclusive worldwide license and option agreement w/ Janssen Biotech, Inc

Genmab's Commitment to Society

Building a Socially Responsible & Sustainable Company

Anchored in our Core Purpose & Vision

- To improve the lives of patients by creating and developing innovative antibody products
- By 2025 our own product has transformed cancer treatment and we have a pipeline of knock-your-socks-off antibodies

CSR Committee comprised of representatives from variety of functions, chaired by CEO

- Ensures that Genmab carries out CSR activities effectively & communicates clearly and openly
- Focus on Environment, Society and Governance reporting

Focus on four main areas

- Employee well-being, including health, safety & development
- Ethics in relation to pre-clinical and clinical studies
- Environment, including waste management & recycling
- Business ethics & transparency

Innovation Powerhouse:
Cutting Edge Proprietary Technologies

Technology		Principle	Applications
DuoBody		Bispecific antibodies	Dual targeting
HexaBody		Target-mediated enhanced hexamerization	Enhanced potency
DuoHexaBody		Bispecific antibodies with target-mediated enhanced hexamerization	Dual targeting + enhanced potency
HexElect		Two co-dependent antibodies with target-mediated enhanced hexamerization	Dual targeting + enhanced potency & selectivity

Innovative Clinical and Pre-Clinical Pipeline

Genmab's Proprietary[1] Products

Product	Target	Developed By	Disease Indications	Most Advanced Development Phase
				Pre-Clinical / 1 / 1/2 / 2 / 3 / Approved
Tisotumab vedotin	TF	50:50 Genmab / Seattle Genetics	Cervical cancer	
			Ovarian cancer	
			Solid tumors	
Enapotamab vedotin	AXL	Genmab	Solid tumors	
Epcoritamab (DuoBody-CD3xCD20)	CD3, CD20	50:50 Genmab / AbbVie	Hematological malignancies	
DuoBody-PD-L1x4-1BB (GEN1046)	PD-L1, 4-1BB	50:50 Genmab / BioNTech	Solid tumors	
HexaBody-DR5/DR5 (GEN1029)	DR5	Genmab	Solid tumors	
DuoBody-CD40x4-1BB (GEN1042)	CD40, 4-1BB	50:50 Genmab / BioNTech	Solid tumors	
DuoHexaBody-CD37 (GEN3009)	CD37	50:50 Genmab / AbbVie	Hematologic malignancies	
DuoBody-CD3x5T4 (GEN1044)	CD3, 5T4	50:50 Genmab / AbbVie	Solid tumors	
IND/CTAs in 2020 HexaBody-CD38 (GEN3014)[2]		Genmab		

[1]Certain product candidates in development with partners, as noted. [2]Genmab is developing HexaBody-CD38 in an exclusive worldwide license and option agreement with Janssen Biotech, Inc

Products Created by Genmab*

Including Proposed Label Expansions for Marketed Products

Product	Target	Developed By	Disease Indications	Most Advanced Development Phase
				Pre-Clinical / 1 / 1/2 / 2 / 3 / Approved
DARZALEX (daratumumab) & **DARZALEX *FASPRO*** (daratumumab and hyaluronidase-fihj)	CD38	Janssen (Tiered royalties to Genmab on net global sales)	Multiple myeloma[1]	3
Daratumumab			AL Amyloidosis	3
			Non-MM blood cancers	2
Kesimpta (ofatumumab)	CD20	Novartis (Royalties to Genmab on net global sales)	Relapsing multiple sclerosis[1]	Approved
Arzerra (ofatumumab)	CD20	Novartis	Chronic lymphocytic leukemia[1,2]	Approved
TEPEZZA (teprotumumab-trbw)	IGF-1R	Horizon Therapeutics (under sublicense from Roche, royalties to Genmab on net global sales)	Thyroid eye disease[1]	Approved
Teprotumumab			Diffuse cutaneous systemic sclerosis	1/2

*Out-licensed products marketed by partner [1]See local country prescribing information for precise indications, [2]Not in active development

Partner-owned Products Incorporating Genmab's Innovation*

Product	Target	Developed By	Disease Indications	Most Advanced Development Phase
				Pre-Clinical / 1 / 1/2 / 2 / 3 / Approved
Amivantamab (JNJ-61186372)	EGFR, cMet	Janssen	Non-small-cell lung cancer (NSCLC)	3
Teclistamab (JNJ-64007957)	BCMA, CD3	Janssen	Relapsed or refractory MM	2
PRV-015 (AMG 714)	IL-15	Provention Bio	Celiac disease	2
Camidanlumab tesirine (ADCT-301)	CD25	ADC Therapeutics	Relapsed /Refractory Hodgkin Lymphoma	2
			Solid tumors	1
Mim8	FIX(a), FX	Novo Nordisk	Healthy volunteers & hemophilia A	1/2
Talquetamab (JNJ-64407564)	GPRC5D, CD3	Janssen	Relapsed or refractory MM	1
JNJ-63709178	CD123, CD3	Janssen	Acute Myeloid Leukemia (AML)	1
JNJ-63898081	PSMA, CD3	Janssen	Solid tumors	1
JNJ-67571244	CD33, CD3	Janssen	Relapsed or refractory AML or MDS	1
JNJ-70218902	Undisclosed	Janssen	Solid tumors	1
HuMax-IL8	IL8	BMS	Advanced cancers	1
Lu AF82422	alpha-Synuclein	Lundbeck	Parkinson's disease	1

*Out-licensed Products under development by a third-party incorporating Genmab technology and innovation

Solid Foundation Built on a Differentiated Pipeline

Tisotumab Vedotin Clinical Program

innovaTV 204

Recurrent or metastatic cervical cancer

- Potentially registrational 102 pts
- Single arm, monotherapy
- 1° endpoint: confirmed ORR
- 2° endpoints: duration of response, PFS, OS

innovaTV 205

Recurrent or metastatic cervical cancer

- In combo or mono
  - w/ bevacizumab, pembrolizumab, or carboplatin or weekly monotherapy recurrent or stage IVB cervical cancer
- Up to 170 pts
- 1° endpoint: ORR
- 2° endpoints: Safety, duration of response, time to response, PFS, OS

innovaTV 207

Solid tumors

- Basket study
- Up to 250 pts
- Single arm, monotherapy
- 1° endpoint: ORR
- 2° endpoints: Safety, disease control rate, duration of response, time to response, PFS, OS

innovaTV 208

Ovarian cancer

- Ovarian cancer, fallopian tube cancer, peritoneal cancer
- Up to 182 pts, incl 12 pt safety run-in
- Monotherapy
- 2 schedules: q3wk & dose dense
- 1° endpoints: Safety & ORR

Tisotumab Vedotin

Cervical Cancer Market Size

United States[3]

New Diagnoses	Deaths
12,578	4,115

3rd most common gynecologic cancer in US[4]

Japan[6]

New Diagnoses	Deaths
9,390	3,654

2nd most common gynecologic cancer in Japan[6]

Europe[2]

New Diagnoses	Deaths
58,373	24,404

3rd most common gynecologic cancer in Europe[2*]

In developed countries, incidence rates are low (<7.9 per 100,000 women) compared with ***developing countries*** in sub-Saharan Africa and Central and South America, where incidence is especially high ***(>30 per 100,000 women)***[5]

*Europe is defined as the 40 countries in the four United Nations-defined areas of Europe and the European Union (EU-27).

References: 1. American Cancer Society **2.** .EUCAN (2012) **3.** Centers for Disease Control and Prevention. Cervical Cancer Statistics (2017) **4.** *UpToDate*. **5.** Ginsburg O et al. *Lancet* 2017 **6.** HPV Information Centre Japan (2017)

HexaBody-CD38 (GEN3014)

Expanding the Potential of CD38 Antibodies

Incorporates proprietary HexaBody technology

Highly promising data pre-clinical models for MM, lymphoma & AML

Could potentially add to and broaden DARZALEX franchise

IND/CTA planned in H2 2020

Covering All Stages of MM and Beyond: Key Ongoing* Industry Sponsored Trials

Disease	Therapy	Development Phase
High Risk Smoldering MM	Subcutaneous	✓ AQUILA
	Monotherapy	✓ CENTAURUS
Front line MM (transplant & non-transplant)	Dara + VRd	✓ CEPHEUS
	Dara + VMP (Asia Pacific)	✓ OCTANS
	Dara + VRd	✓ PERSEUS
	Dara + R (maintenance)	AURIGA
Relapsed or Refractory MM	Dara + combinations	NINLARO® (Ph II), Venclexta® (Ph II), Selinexor (Ph I/II)
	Dara + I.O. (PD1 & PDL1)	Opdivo® (Ph I/II), Tecentriq® (Ph I)
ALL	Dara + SoC chemo	DELPHINUS



V = Velcade® , MP = melphalan-prednisone , T = thalidomide d = dexamethasone, R = Revlilmid®, K = Kyprolis®, Pom = Pomalyst®
✓ Fully recruited

*Does not include trials that may still be ongoing but have clinical data and/ or are the basis for an existing approval.

Daratumumab Efficacy in Newly Diagnosed Multiple Myeloma

Updated Phase 3 MAIA Trial (D+Rd, NTE): ASH Dec 2019



PFS, progression-free survival; D-Rd, daratumumab/lenalidomide/dexamethasone; Rd, lenalidomide/dexamethasone; NR, not reached; HR, hazard ratio; CI, confidence interval.

- Median PFS not reached in D-Rd arm
- MRD-negativity significantly higher with D-Rd vs. Rd (29% vs 9%; P<0.0001)
- No new safety concerns
- Results continue to support use of D-Rd in 1st line treatment of TIE pts with NDMM

D = daratumumab; R = lenalidomide; d = dexamethasone; PFS = progression free survival; MRD – minimal residual disease

Ongoing Daratumumab Clinical Trials

Janssen Sponsored Phase 3 & 4

Daratumumab Trials Sponsored by Pharma / Biotech

Ct.gov Identifier	Phase	Sponsor	Indication	Therapy
NCT03768960	4	J&J Private Ltd	Relapsed or Refractory MM	Daratumumab (MMY4008)
NCT02252172	3	Janssen	Untreated MM	Daratumumab + Rd (MAIA)
NCT02195479	3	Janssen	Untreated MM	Daratumumab + VMP (ALCYONE)
NCT02541383	3	Janssen	Untreated MM	Daratumumab + VTd (CASSIOPEIA)
NCT02076009	3	Janssen	Relapsed or Refractory MM	Daratumumab + Rd (POLLUX)
NCT02136134	3	Janssen	Relapsed or Refractory MM	Daratumumab + Vd (CASTOR)
NCT03180736	3	Janssen	Relapsed or Refractory MM	Daratumumab + Pom-d (APOLLO)
NCT03201965	3	Janssen	Amyloidosis	Daratumumab + CyBorD (ANDROMEDA)
NCT03217812	3	Janssen	Untreated MM	Daratumumab + VMP (Asia Pacific) (OCTANS)
NCT03234972	3	Janssen	Relapsed or Refractory MM	Daratumumab + Vd vs Vd (LEPUS)
NCT03277105	3	Janssen	Relapsed or Refractory MM	Daratumumab SubQ vs IV (COLUMBA)
NCT03301220	3	Janssen	Smoldering MM	Daratumumab SubQ (AQUILA)
NCT03652064	3	Janssen	Untreated MM	Daratumumab + VRd (CEPHEUS)
NCT03710603	3	Janssen/EMN	Untreated MM	Daratumumab + VRd (PERSEUS)
NCT03901963	3	Janssen	Untreated MM / Maintenance	Daratumumab + R (AURIGA)

Ongoing Daratumumab Clinical Trials

Janssen Sponsored Phase 1 & 2

Daratumumab Trials Sponsored by Pharma / Biotech

Ct.gov Identifier	Phase	Sponsor	Indication	Therapy
NCT03384654	2	Janssen	Relapsed / Refractory ALL / LL	Dara + Vincristine + Prednisone + Doxorubicin (DELPHINUS)
NCT02951819	2	Janssen	Untreated and Relapsed MM	Daratumumab + CyBorD (LYRA)
NCT02874742	2	Janssen	Untreated MM	Daratumumab + VRd (GRIFFIN)
NCT02316106	2	Janssen	Smoldering MM	Monotherapy (CENTAURUS)
NCT02927925	2	Janssen	NKTCL, Nasal Type	Monotherapy (VOLANS)
NCT03412565	2	Janssen	Newly diag. & relapsed / refractory MM	Daratumumab SubQ + Rd, VMP & VRd (PLEIADES)
NCT03871829	2	Janssen	Dara retreatment	Daratumumab SubQ+ Kd vs Kd (LYNX)
NCT03011034	2	Janssen	MDS	Daratumumab (or talacotuzumab) (MDS2002)
NCT01615029	1/2	Janssen	Relapsed and Refractory MM	Daratumumab + Rd (GEN503)
NCT02852837	1	Janssen	Relapsed or Refractory MM	Monotherapy (in China) (MMY1003)
NCT02519452	1	Janssen	Relapsed or Refractory MM	Monotherapy, subcutaneous (PAVO)
NCT02918331	1	Janssen	Untreated MM	Daratumumab + Rd (Japan) (MMY1006)
NCT03242889	1	Janssen	Relapsed or Refractory MM	Daratumumab subq (Japan) (MMY1008)
NCT01998971	1	Janssen	Various MM	Daratumumab + backbone regimens (Vd, VMP, VTd, Pom-d, Kd, KRd) (EQUULEUS)
NCT04108195	1	Janssen	Multiple Myeloma	Daratumuamb + either talquetamab or teclistamab (MMY1002)
NCT04121260	1	Janssen	Multiple Myeloma	Subcutaneous monotherapy (in China) (MMY1010)

Ongoing Daratumumab Clinical Trials

Other Industry Sponsored Trials

Daratumumab Trials Sponsored by Pharma / Biotech

Ct.gov Identifier	Phase	Sponsor	Indication	Therapy
NCT03158688	3	Amgen	Relapsed or Refractory MM	Daratumumab + Kd (CANDOR)
NCT01946477	2	Celgene	Relapsed or Refractory MM	Daratumumab + Pom-d
NCT02807454	2	Celgene	Relapsed and Refractory MM	Daratumumab + Imfinzi (FUSION)
NCT03439293	2	Takeda	Relapsed or Refractory MM	Daratumumab + NINLARO (ixazomib) + Dex
NCT03314181	2	AbbVie	Relapsed or Refractory MM	Daratumumab + Venetoclax + Dex (w/ or w/out bortezomib)
NCT02807558	2	Syros Pharma	AML or MDS	Daratumumab + SY-1425
NCT02773030	1/2	Celgene	Relapsed or Refractory MM	Daratumumab + CC-220 + Dex
NCT02343042	1/2	Karyopharm	Relapsed or Refractory MM	Daratumumab + Selinexor + Dex (STOMP)
NCT03481556	1/2	Oncopeptides AB	Relapsed or Refractory MM	Daratumumab + Melflufen + Dex (ANCHOR)
NCT01592370	1/2	BMS	Relapsed or Refractory MM	Daratumumab + nivolumab
NCT03837509	1/2	Incyte	Relapsed or Refractory MM	Daratumumab + INCB001158
NCT03989414	1/2	Celgene	Various MM	Daratumumab + CC-92480
NCT02431208	1	Roche	Resistant or Refractory MM	Daratumumab + Tecentriq (atezolizumab)
NCT03068351	1	Roche	Resistant or Refractory MM	Daratumumab + RO6870810
NCT04045028	1	Genentech	Relapsed or Refractory MM	Daratumumab + tiragolumab
NCT04136756	1	Nektar Thera.	Salvage for MM	Daratumumab + NKTR-255